go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Pfizer Consumer Healthcare

Pfizer Consumer Healthcare
9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 (0)1 467 6500
Fax: +353 (0)1 467 6501
Medical Information Direct Line: +353 (0)1 467 6627


Summary of Product Characteristics last updated on medicines.ie: 14/11/2011
SPC Robitussin Plus

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipients
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Robitussin Plus Oral Solution

Guaifenesin 100 mg/5ml

Pseudoephedrine HCl 30 mg/5ml


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml of liquid contains:

Guaifenesin

100 mg

Pseudoephedrine HCl

30 mg

 

 

Excipients:

 

Each 5ml contains;

 

Ethanol (96%)

110 mg

Sodium

13.6 mg

Amaranth

0.033 mg

Liquid Maltitol

242 mg

Sorbitol Solution 70%

1.454 g

For a full list of excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Oral solution.

A clear, pale pink-coloured liquid with a cherry flavour.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Fixed combination of sympathomimetic and expectorant for use as a nasal decongestant and expectorant.


Go to top of the page
4.2 Posology and method of administration

Taken orally.

Adults and children over 12 years:

10 ml x 3 daily

Children under 12:

Do not use


Go to top of the page
4.3 Contraindications

Use in children under 12 years of age.

Hypersensitivity to the active substance or to any of the excipients.

Persons with hypertension, acute ischaemic heart disease, glaucoma, thyrotoxicosis or urinary retention, should use this product only as directed by a doctor

Patients currently receiving, or who have received within two weeks, monoamine oxidase inhibitors

Patients receiving other sympathominetic agents or tricyclic antidepressants


Go to top of the page
4.4 Special warnings and precautions for use

Caution should be exercised in patients with:

- High blood pressure, heart disease, diabetes, thyroid disease, or trouble urinating due to enlarges prostate gland.

-A chronic cough occurs as occurs with smoking or chronic lung disease such as asthma or emphysema.

It should be used only cautiously in patients with severe hepatic or renal impairment.

Pregnant of lactating women should consult their doctor before use.

Keep out of the reach and sight of children.

A doctor or healthcare professional should be sought if symptoms get worse or last more than 5 days, come back or are accompanied by fever, rash or persistent headaches. These could be signs of a serious condition.

This medicinal product contains 13.6mg sodium per 5ml. To be taken into consideration by patients on a controlled sodium diet.

This product contains 2.3 % w/v per 5 ml of ethanol (96%) which should be taken into consideration for those suffering from alcoholism, those who are pregnant or breastfeeding or high risk groups such as patients suffering from liver disease or epilepsy.

This product contains amaranth (E123) which may cause allergic reactions.

Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Do not exceed recommended dose.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Do not take this product if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 14 days after stopping the MAOI drug.

Patients receiving cardiac glycosides or antihypertensive agents should use this product only as directed by a doctor.


Go to top of the page
4.6 Pregnancy and lactation

Consult a doctor before use.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

The following side effects may be associated with the use of these active ingredients and are listed under their corresponding body system organ class:

Immune system disorders

Hypersensitivity

Psychiatric disorders

Agitation, anxiety, excitability, insomnia, irritability, nervousness, restlessness

Nervous system disorders

Dizziness, headache, psychomotor hyperactivity

Cardiac Disorders

Palpitation, tachycardia

Vascular disorders

Hypertension, increased blood pressure

Gastrointestinal disorders

Nausea, vomiting

Skin and subcutaneous tissue disorders

Rash, urticaria


Go to top of the page
4.9 Overdose

The following side effects may be associated with an overdose of these actives ingredients:

Gastrointestinal disorders

Nausea, vomiting

Cardiac disorders

Bradycardia, palpitation, tachycardia

Nervous system disorders

Convulsion, dizziness, tremor

Psychiatric disorders

Agitation, anxiety, insomnia, irritability, nervousness, restlessness

Vascular disorders

Hypertension, increased blood pressure

Treatment is by gastric lavage together with appropriate supportive therapy dependent upon individual response to the various constituents of the product.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Guaifenesin is used as an expectorant. It reduces the viscosity of the sputum.

Pseudoephedrine reduces swollen nasal membranes, tissue hyperaemia, oedema and nasal congestion. It increases nasal airway patency and reduces eustachian tube blockage.


Go to top of the page
5.2 Pharmacokinetic properties

Guaifenesin is absorbed from the GI tract. It undergoes metabolism and is excreted in the urine.

Pseudoephedrine is absorbed from the GI tract. It is incompletely metabolised in the liver. It is excreted both as unchanged pseudoephedrine and as metabolites in the urine.


Go to top of the page
5.3 Preclinical safety data

Not Applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Ethanol (96%)

Glycerol

Carmellose Sodium

Sodium Benzoate (E211)

Caramel (E150)

Disodium Edetate

Amaranth (E123)

Citric Acid Anhydrous

Levomenthol

Maltitol Liquid (E965)

Natural Cherry Flavour*

Sorbitol Solution (70%) (E420)

Sodium Cyclamate

Acesulfame Potassium Salt

Purified Water

* contains Ethanol, Propylene Glycol and Natural Cherry Flavour


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

PET Bottles: 3 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Do not refrigerate or freeze.


Go to top of the page
6.5 Nature and contents of container

PET bottles containing 100ml with PET lined PP/HDPE screw caps.

A clear polypropylene measuring cap is also included.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Pfizer Consumer Healthcare Ltd,

Ramsgate Road, Sandwich,

Kent, CT13 9NJ,

United Kingdom.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 172/35/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29th July 1985

Date of last renewal: 29th July 2010


Go to top of the page
10. DATE OF REVISION OF THE TEXT

September 2011



Link to this document from your website:
http://www.medicines.ie/medicine/2986/SPC/Robitussin+Plus/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Guaifenesin
   Pseudoephedrine Hydrochloride

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo